Sybill Hessler

Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer

Martin Reck, Joachim von Pawel, Hans-Nicolas Macha et al. · JNCI Journal of the National Cancer Institute · 2003 · 97 citations

Medicine, Oncology, Pharmacology +14

Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years’-follow-up results from a randomised phase III trial

Martin Reck, Joachim von Pawel, Hans-Nicholas Macha et al. · Lung Cancer · 2006 · 26 citations

Medicine, Oncology, Pharmacology +17

A phase III trial of taxol, etoposide phosphate and carboplatin (TEC) versus carboplatin, etoposide phosphate and vincristine (CEV) in previously untreated small cell lung cancer (SCLC)

U Gatzemeier, Bernhard Faderl, H.-N. Macha et al. · Lung Cancer · 2000 · 13 citations

Medicine, Oncology, Pharmacology +11

Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide—A phase II study

Martin Reck, U. Jagos, Franziska Grunwald et al. · Lung Cancer · 2002 · 12 citations

Medicine, Oncology, Pharmacology +7